Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder.

Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore.
Immunology (Impact Factor: 3.71). 08/2008; 124(3):419-27. DOI: 10.1111/j.1365-2567.2007.02792.x
Source: PubMed

ABSTRACT Mycobacterium bovis, bacillus Calmette-Guérin (BCG) is the current gold standard for bladder cancer therapy. In this study a profile of the gene expression changes that occur after BCG instillation in the bladders of healthy mice was produced and compared to the type of immune cells recruited into the bladder. A similar comparison was made for Lactobacillus rhamnosus strain GG (LGG) instillations in healthy mice to determine its potential in the immunotherapy of bladder cancer. Mice were given six weekly instillations and were killed after the fourth, fifth and sixth instillations of BCG or LGG. Their bladders were harvested for chemokine/cytokine messenger RNA analysis using an array as well as semi-quantitative reverse transcription-polymerase chain reaction. In a second set of mice both the bladder and draining lymph nodes were harvested for the analysis of immune cells. BCG significantly upregulated genes for T helper type 1 (Th1) chemokines: Cxcl2, Cxcl9, Cxcl10, Xcl1; and increased the expression of Th1/Th2 chemokines: RANTES, Ccl6 and Ccl7; Th1 polarizing cytokines: Il1beta and Tnfa; and Fcgammar1 and iNOS as early as after four weekly instillations. Most of these genes remained highly expressed after 6 weeks. In contrast, LGG transiently induced Cxcl10, Il16, Fcepsilonr1 and Il1r2. Despite these findings, LGG instillation induced the recruitment of natural killer cells into the bladder and draining lymph nodes, as was observed for BCG instillation.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present gold standard for bladder cancer is Mycobacterium bovis, Bacillus Calmette Guerin (BCG) immunotherapy. But it has a non-responder rate of 30-50% and side effects are common. Lactobacillus casei strain Shirota has been reported to reduce the incidence of recurrence in bladder cancer patients and to cure tumor-bearing mice. Our aim was to determine if Lactobacillus rhamnosus GG (LGG) could be as efficacious as BCG in a murine model of bladder cancer. MB49 bladder cancer cells secreting human prostate-specific antigen were implanted orthotopically in female C57BL/6 mice and urinary prostate-specific antigen levels were used as a marker of tumor growth. Mice were treated with either live or lyophilized LGG given via intravesical instillation, or both oral and intravesical LGG given once a week for a period of 6 weeks starting at day 4 after tumor implantation. A comparison of LGG and BCG immunotherapy was also carried out. LGG therapy (live or lyophilized) significantly (P = 0.006) increased the number of cured mice. Cytokine arrays and immune cell recruitment analysis revealed differences between untreated, treated, cured, and tumor-bearing mice. LGG therapy restored XCL1 levels to those in healthy bladders. LGG also recruited large numbers of neutrophils and macrophages to the tumor site. Intravesical LGG and BCG immunotherapy had cure rates of 89 and 77%, respectively, compared with 20% in untreated mice. LGG has the potential to replace BCG immunotherapy for the treatment of bladder cancer.
    Cancer Science 11/2009; 101(3):751-8. · 3.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: CXCL10 production is a critical step in limiting mycobacterial infection. Although induction of this chemokine by mycobacteria in epithelial cells has been reported, it is still unclear how CXCL10 is regulated in Mycobacterium bovis BCG-infected epithelial cells. In this study, we demonstrate that phosphatidylinoditol 3-kinase (PI3K)/Akt and the nuclear factor kB (NF-kB) signaling pathways play an important role in CXCL10 expression at the protein and mRNA level in A549 cells. We demonstrate that treatment of A549 cells with LY294002 and wortmannin, two PI3K inhibitors, inhibited M. bovis BCG-induced CXCL10 expression. In addition, treatment of A549 cells with an Akt inhibitor significantly blocked M. bovis BCG-induced CXCL10 production. Moreover, our data show that treatment of epithelial cells with CAPE, BAY 11-7082, and PDTC three selective inhibitors of NF-kB, significantly reduced the effect of M. bovis BCG on induced CXCL10 mRNA expression (74%, 69% and 83% inhibition by 8microM CAPE, 10microM BAY 11-7082 and 3microM PDTC as assessed by real-time PCR, respectively). In accordance with the gene induction, the production of CXCL10 was also significantly reduced by these inhibitors. Finally, the inhibition of PI3K affect NF-kB activation in M. bovis BCG-infected cells, indicating that PI3K activity is required for the M. bovis BCG-induced activation of NF-kB. The functional association between PI3K/Akt and NF-kB demonstrates another mechanism in the regulation of M. bovis BCG-induced CXCL10 in A549 cells.
    Cellular Immunology 02/2009; 256(1-2):12-8. · 1.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to monitor changes in the expression of immune-related genes in the bladder after tumor implantation. Mice were orthotopically implanted with MB49-PSA cells (C57BL/6 mice) on day 1 and terminated on days 7, 14, 21, and 28. Another mouse model (MBT-2/C3H mice) was examined at day 7. Gene expression analysis was performed using a TaqMan Low Density Mouse Immune Panel (Applied Biosystems, USA) on RNA extracted from the bladders. Selected genes were reconfirmed by real-time PCR analysis and RT-PCR on the mRNA from other animals. Immune suppressive (IL13, IL1β, PTGS2, NOS2, IL10, CTLA4, and CCL22) and immune stimulatory genes (CSF2, GZMB, IFNγ, CXCL10, TNFα, CD80, IL12a, and IL6) and AGTR2 were increased by day 7. By day 28, IL10, CCL2, CCL5, CXCL11, CTLA4, GZMB, IFNγ, CSF2, and IL6 were significantly increased. Therapeutic strategies involving TH1 induction and TH2 dampening may improve responses to immunotherapy.
    Clinical and Developmental Immunology 01/2011; 2011:865684. · 3.06 Impact Factor

Full-text (2 Sources)

Available from
May 16, 2014